TORECAN
LOE ApproachingNDARECTALSUPPOSITORY
Approved
Apr 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORECAN is a small-molecule rectal suppository approved in 1963 by Novartis for unspecified indications. The drug's mechanism of action and pharmacologic class are not publicly detailed in available data, limiting assessment of its current clinical role.
LOE Approaching
As a 60+ year-old product approaching loss of exclusivity with minimal current market activity, the brand team is likely focused on cost management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TORECAN is a legacy brand with zero linked job openings and minimal career development potential. Assignment to this product typically reflects portfolio maintenance or transition management responsibilities rather than growth or innovation opportunities.
Brand ManagerProduct Manager
Worked on TORECAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.